cysteamine has been researched along with fenofibrate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frants, RR; Havekes, LM; Hoffer, MJ; Kibirige, MS; Naoumova, RP; Niththyananthan, S; Thompson, GR | 1 |
1 review(s) available for cysteamine and fenofibrate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for cysteamine and fenofibrate
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Cysteamine; Dinucleotide Repeats; DNA; Electrophoresis; Exons; Female; Fenofibrate; Genotype; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Immunoblotting; Male; Nuclear Family; Phenotype; Point Mutation; Radiation-Protective Agents; Triglycerides | 1996 |